Last reviewed · How we verify

Behçet's disease affecting oral mucosa — Treatment Landscape & Competitive Intelligence

Behçet's disease affecting oral mucosa (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Behçet's disease affecting oral mucosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Otezla APREMILAST Amgen Phosphodiesterase 4 Inhibitor [EPC] PDE4 2014-01-01
Otezla Otezla L.H. Kircik, M.D. cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Amgen · 1 drug in Behçet's disease affecting oral mucosa
  2. L.H. Kircik, M.D. · 1 drug in Behçet's disease affecting oral mucosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Behçet's disease affecting oral mucosa:

Cite this brief

Drug Landscape (2026). Behçet's disease affecting oral mucosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/beh-et-s-disease-affecting-oral-mucosa. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing